Hypoprothrombinemia Treatment Market Report 2026

The hypoprothrombinemia treatment market size has grown strongly in recent years. It will grow from $1.52 billion in 2025 to $1.65 billion in 2026 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to vitamin k deficiency prevalence, liver disease complications, anticoagulant overuse, hospital transfusion protocols, inherited clotting disorders.

The hypoprothrombinemia treatment market size is expected to see strong growth in the next few years. It will grow to $2.3 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to advances in recombinant clotting factors, improved emergency care infrastructure, aging population bleeding risks, precision hematology adoption, outpatient coagulation management. Major trends in the forecast period include increased use of prothrombin complex concentrates, growing reliance on rapid coagulation correction therapies, expansion of vitamin k-based treatment protocols, improved emergency bleeding management standards, rising adoption of recombinant coagulation factors.

The rising prevalence of bleeding disorders is expected to drive growth in the hypoprothrombinemia treatment market. Bleeding disorders are conditions in which the blood does not clot properly, leading to excessive or prolonged bleeding. This increase is primarily due to improved diagnostic capabilities and heightened awareness, which enable more accurate identification and reporting of these conditions. Hypoprothrombinemia treatments help restore blood clotting ability in patients by replenishing deficient prothrombin levels. For example, according to BMC Health Services Research in November 2024, between April 2022 and March 2023 in the United Kingdom, 6,662 males were diagnosed with hemophilia A, of whom 5,032 were adults, and 2,421 received treatment with either factor replacement therapy or emicizumab. During the same period, 1,342 males were identified with hemophilia B, including 1,022 adults, of whom 479 received factor replacement therapy. Therefore, the rising prevalence of bleeding disorders is expected to propel growth in the hypoprothrombinemia treatment market.

The increasing use of biosimilars is also expected to drive the growth of the hypoprothrombinemia treatment market. Biosimilars are biologic medical products that are highly similar to an already approved original biologic, with no clinically meaningful differences in safety or effectiveness. Their rising use is driven by their ability to provide more affordable and accessible treatment options while maintaining comparable safety and efficacy to original biologics. In hypoprothrombinemia treatment, biosimilars provide cost-effective alternatives to original clotting factor therapies, improving patient access to essential coagulation management. For instance, according to Cardinal Health Inc. in January 2023, as of January 2022, the U.S. had 33 FDA-approved biosimilar products, 21 of which were commercially available. By 2023, the number of FDA-approved biosimilars had increased to 40, with 25 on the market. Consequently, the growing adoption of biosimilars is driving growth in the hypoprothrombinemia treatment market.

Leading companies in the hypoprothrombinemia treatment market are focusing on innovative therapies, such as non-activated four-factor prothrombin complex concentrates, to rapidly restore clotting factor levels and reduce bleeding risks in patients requiring urgent reversal of anticoagulation. Non-activated four-factor prothrombin complex concentrate (4F-PCC) is a plasma-derived therapy containing clotting factors II, VII, IX, and X, used to quickly reverse the effects of vitamin K antagonists and treat bleeding disorders such as hypoprothrombinemia. For example, in January 2024, Octapharma USA, a U.S.-based subsidiary of Octapharma AG, launched Balfaxar, a 4F-PCC recently approved by the FDA for the urgent reversal of vitamin K antagonist-induced coagulation deficiencies in adults undergoing emergency surgery or invasive procedures. This therapy, containing essential vitamin K-dependent clotting factors and antithrombotic proteins, addresses critical needs in hypoprothrombinemia management.

Major companies operating in the hypoprothrombinemia treatment market are Biotest AG, Kedrion Biopharma, LFB S.A., Hualan Biological Engineering Inc., China Biologic Products Holdings Inc., Bio Products Laboratory (BPL), Kamada Ltd., Green Cross Corporation, Shanghai RAAS Blood Products Co. Ltd., SK Plasma Co. Ltd., Emergent BioSolutions Inc., Intas Pharmaceuticals Ltd., Bharat Serums and Vaccines Ltd., ZLB Behring (CSL Behring), Mitsubishi Tanabe Pharma Corporation.

North America was the largest region in the hypoprothrombinemia treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hypoprothrombinemia treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hypoprothrombinemia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have increased costs in the hypoprothrombinemia treatment market by affecting imports of vitamin K, plasma-derived products, and recombinant coagulation factors. Injectable and transfusion-based therapies are most impacted, particularly in North America and Europe. Hospitals and specialty clinics face higher treatment expenses. Positively, tariffs are encouraging local production of clotting factor concentrates and plasma therapies.

The hypoprothrombinemia treatment market research report is one of a series of new reports that provides hypoprothrombinemia treatment market statistics, including hypoprothrombinemia treatment industry global market size, regional shares, competitors with a hypoprothrombinemia treatment market share, detailed hypoprothrombinemia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the hypoprothrombinemia treatment industry. This hypoprothrombinemia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hypoprothrombinemia treatment involves medical approaches aimed at restoring sufficient levels of prothrombin (Factor II), a crucial protein for blood clotting. The goal is to prevent or manage abnormal bleeding by addressing the underlying deficiency, which may result from genetic causes, vitamin K deficiency, liver disorders, or excessive use of anticoagulants.

Treatment for hypoprothrombinemia mainly includes Type I deficiency treatment and Type II deficiency treatment. Type I hypoprothrombinemia (true prothrombin deficiency) is generally managed with prothrombin complex concentrates (PCCs) or fresh frozen plasma (FFP) to replenish prothrombin levels and improve clotting function. Available drug options include vitamin K, fresh frozen plasma, prothrombin complex concentrates, and recombinant prothrombin. These treatments are used for conditions such as vitamin K deficiency, liver diseases, cirrhosis, hepatitis, anticoagulant-induced hypoprothrombinemia, genetic disorders, and malabsorption syndromes. Administration routes include oral, injectable, intravenous, intramuscular, and transfusion-based delivery, with primary end users being hospitals, specialty clinics, and homecare settings.

The hypoprothrombinemia treatment market consists of revenues earned by entities by providing services such as diagnostic testing, hospital care, specialized transfusion services, therapeutic drug monitoring, and patient management programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The hypoprothrombinemia treatment market also includes sales of plasma-derived concentrates, synthetic clotting factors, oral anticoagulant reversal agents, blood products, and plasma derivatives. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.